Status:
COMPLETED
Bio-behavioral Lung Cancer Prevention Program
Lead Sponsor:
National Institutes of Health (NIH)
Conditions:
Smoking Cessation
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The overall goal of this research is to increase our understanding of the role of individual genetic differences in response to bupropion treatment and the psychobiological mechanisms by which genetic...
Eligibility Criteria
Inclusion
- Eligible smokers will be those currently smoking at least 10 cigarettes a day.
Exclusion
- Exclusionary criteria are: planning a pregnancy, pregnancy, lactating, seizure disorder, history of head trauma or prior seizure, family history of a seizure disorder, brain (or CNS) tumor, history of or currently diagnosed with bulimia or anorexia nervosa, diabetes treated with oral hypoglycemics or insulin, excessive use of alcohol or alcoholism, current addiction to opiates, cocaine, or stimulants, use of other drugs containing bupropion (e.g., Wellbutrin, Wellbutrin SR), allergy to bupropion, currently taking particular medications (e.g., monoamine oxidase inhibitor, antipsychotics, antidepressants, theophylline, systemic steroids, over-the-counter stimulants and anorectics), recently taken a MAOI (less than 14 days) or a recent discontinuation of a benzodiazepine.
Key Trial Info
Start Date :
June 1 1999
Trial Type :
INTERVENTIONAL
End Date :
March 1 2002
Estimated Enrollment :
555 Patients enrolled
Trial Details
Trial ID
NCT00322205
Start Date
June 1 1999
End Date
March 1 2002
Last Update
January 11 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
State University of New York
Buffalo, New York, United States